GRAND PHARMA (00512) · Company profile · Eqvero

GRAND PHARMA

00512HKEX

Unit: HKD	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	12.28 bn HKD	11.64 bn HKD	10.53 bn HKD	9.56 bn HKD	8.6 bn HKD
Cost of revenue	4.92 bn HKD	4.4 bn HKD	3.61 bn HKD	3.22 bn HKD	3.01 bn HKD
Research and development expense	502.89 m HKD	588.14 m HKD	571.99 m HKD	531.92 m HKD	331.42 m HKD
Selling, general and administrative expense	5.2 bn HKD	4.62 bn HKD	3.8 bn HKD	3.4 bn HKD	3.31 bn HKD
Operating profit after depreciation	1.77 bn HKD	2.22 bn HKD	2.86 bn HKD	2.75 bn HKD	2.18 bn HKD
Operating profit before depreciation	2.35 bn HKD	2.72 bn HKD	3.25 bn HKD	3.14 bn HKD	2.52 bn HKD
EBIT	1.77 bn HKD	2.22 bn HKD	2.86 bn HKD	2.75 bn HKD	2.18 bn HKD
EBITDA	2.35 bn HKD	2.72 bn HKD	3.25 bn HKD	3.14 bn HKD	2.52 bn HKD
Interest expense	162.34 m HKD	180.24 m HKD	205.15 m HKD	137.49 m HKD	92.96 m HKD
Profit before tax	1.49 bn HKD	2.85 bn HKD	2.34 bn HKD	2.52 bn HKD	2.79 bn HKD
Income tax expense	249.78 m HKD	386.3 m HKD	448.76 m HKD	418.64 m HKD	380.8 m HKD
Income before extraordinary items	1.24 bn HKD	2.47 bn HKD	1.88 bn HKD	2.08 bn HKD	2.4 bn HKD
Common dividends	591.81 m HKD	910.47 m HKD	905.14 m HKD	496.94 m HKD	390.45 m HKD
Total dividends	591.81 m HKD	910.47 m HKD	905.14 m HKD	496.94 m HKD	390.45 m HKD

Quotes are end-of-day data. Content is for research purposes and is not investment advice.